Drug Interaction With Genes in Parkinson's Disease (DIGPD)

This study is currently recruiting participants. (see Contacts and Locations)

Verified November 2013 by Assistance Publique - Hôpitaux de Paris

Sponsor:

Information provided by (Responsible Party):

Assistance Publique - Hôpitaux de Paris

ClinicalTrials.gov Identifier:

NCT01564992

First received: February 23, 2012

Last updated: November 13, 2013

Last verified: November 2013

History of Changes

Purpose

This observational study aims at identifying gene modifiers of Parkinson Disease (PD) and of treatment response and adverse events of antiparkinsonian drugs. Six hundred PD patients will be followed annually for up to 5 years. A biological collection will be associated with a full clinical assessment of motor and non motor symptoms, medical and treatment history, environmental factors. The association between candidate gene polymorphisms and disease or treatment complications will be analyzed.

Condition	Intervention
Parkinson's Disease	Other: Identification of genes


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Drug Interaction With Genes in Parkinson's Disease

Resource links provided by NLM:

Genetics Home Reference related topics: Parkinson disease Perry syndrome

MedlinePlus related topics: Drug Reactions Genes and Gene Therapy Parkinson's Disease

U.S. FDA Resources

Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:

All complications of the disease or treatment [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Biospecimen Retention: Samples With DNA

blood


Estimated Enrollment:	600
Study Start Date:	March 2009
Estimated Study Completion Date:	March 2014
Estimated Primary Completion Date:	March 2014 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
Parkinson disease	Other: Identification of genes Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment. Other Name: polymorphism or haplotype

Detailed Description:

Title : Drug interaction with genes in Parkinson Disease

Objective:

To identify genes associated to disease and treatment complication and response.

Number of subjects: 600

Study duration : 5 years

Design:

Prospective cohort with biological collection

Primary objective:

Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.

Secondary objectives:

Prevalence and incidence of disease or treatment complications
Clinical risk factor for disease or treatment complications
Biomarkers of disease progression, disease or treatment complications

Eligibility


Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Men and women adults with a Parkinson Disease according to UKPDSBB criteria, diagnosed < 6 years

Criteria

Inclusion Criteria:

Men and women, age > 18.
Parkinson Disease according to UKPDSBB criteria
PD diagnosis < 6 years
Informed consent

Exclusion Criteria:

- Atypical parkinsonism

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01564992

Contacts


Contact: Jean-Christophe Corvol, MD, PhD	+33 1 42 16 57 66

Locations


France
Centre d'Investigation Clinique Neuro - Bâtiment ICM - Hôpital Pitié-Salpêtrière	Recruiting
Paris, France, 75013
Contact: Jean-Christophe Corvol, MD, PhD +33 1 42 16 57 66
Principal Investigator: Jean-Christophe Corvol, MD, PhD

Sponsors and Collaborators

Assistance Publique - Hôpitaux de Paris

Investigators


Principal Investigator:	Jean-Christophe Corvol, MD, PhD	Asssitance Publique - Hopitaux de Paris

More Information

No publications provided


Responsible Party:	Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:	NCT01564992 History of Changes
Other Study ID Numbers:	P 071240
Study First Received:	February 23, 2012
Last Updated:	November 13, 2013
Health Authority:	France: Ministry of Health

Keywords provided by Assistance Publique - Hôpitaux de Paris:


Parkinson's disease Pharmacogenetics Genetics

Additional relevant MeSH terms:


Parkinson Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases	Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinsonian Disorders

ClinicalTrials.gov processed this record on March 01, 2015

To Top